ResearcherNational Institutes of HealthActive in the last 2 years
S. S. Yang
Matched on ORCID iD 0000-0003-1959-2344; OpenAlex author ID A5022611196. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2024: 3 papers
Papers 3
- LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism. Co-author DOI 10.1093/carcin/bgae011↗
- MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways. Co-author DOI 10.1093/carcin/bgae025↗
- ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. Co-author DOI 10.1093/carcin/bgae056↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Nader N Hanna · 3 shared papers, 2024 · strength 0.56
- Paper LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through… DOI 10.1093/carcin/bgae011↗
- Paper ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. DOI 10.1093/carcin/bgae056↗
- Paper MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways. DOI 10.1093/carcin/bgae025↗
- Michael B. Ghadimi · 3 shared papers, 2024 · strength 0.56
- Paper LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through… DOI 10.1093/carcin/bgae011↗
- Paper ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. DOI 10.1093/carcin/bgae056↗
- Paper MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways. DOI 10.1093/carcin/bgae025↗
- Jochen Gaedcke · 3 shared papers, 2024 · strength 0.56
- Paper LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through… DOI 10.1093/carcin/bgae011↗
- Paper ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. DOI 10.1093/carcin/bgae056↗
- Paper MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways. DOI 10.1093/carcin/bgae025↗
- Yuuki Ohara · 3 shared papers, 2024 · strength 0.56
- Paper LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through… DOI 10.1093/carcin/bgae011↗
- Paper ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. DOI 10.1093/carcin/bgae056↗
- Paper MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways. DOI 10.1093/carcin/bgae025↗
- Azadeh Azizian · 3 shared papers, 2024 · strength 0.56
- Paper LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through… DOI 10.1093/carcin/bgae011↗
- Paper ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. DOI 10.1093/carcin/bgae056↗
- Paper MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways. DOI 10.1093/carcin/bgae025↗
- S. Perwez Hussain · 3 shared papers, 2024 · strength 0.56
- Paper LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through… DOI 10.1093/carcin/bgae011↗
- Paper ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. DOI 10.1093/carcin/bgae056↗
- Paper MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways. DOI 10.1093/carcin/bgae025↗
- Paloma Moreno · 2 shared papers, 2024 · strength 0.37
- Lin Zhang · 1 shared paper, 2024 · strength 0.18
- Jianjun Gao · 1 shared paper, 2024 · strength 0.18
- Subrata Sen · 1 shared paper, 2024 · strength 0.18
- Nagireddy Putluri · 1 shared paper, 2024 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.